Eagle Pharmaceuticals Stock (NASDAQ: EGRX)

Eagle Pharmaceuticals Stock (NASDAQ:EGRX), Trade Ideas

Eagle Pharmaceuticals

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ATXI

AULT

BDRX

BILI

BIVI

BMEA

CCRD

Envoy Medical, Inc. - Class A Common Stock

COCH

CPHI

CRWD

CVNA

DERM

EGRX

ESGL

FLNC

FTCH

HNRA

LESL

NTAP

OKTA

PDCO

PHGE

RDHL

ROVR

SEEL

VCXA

VERV

VTVT

VVOS

WDAY

WOOF

YOSH

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Biotech

Equities

Health Care

Management

General

Eagle Pharmaceuticals Inc&#39;s (NASDAQ: EGRX) Scott Tarriff, founder, president, and Chief Executive Officer, announced his resignation and retirement, 

Why Is Eagle Pharmaceuticals Stock Trading Lower Today?

Long Ideas

Pre-Market Outlook

AFIB

VTYX

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Blast Off This Quarter

Eagle Pharmaceuticals, Inc. - Common Stock

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals To Present Additional Data from Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference

Eagle Pharmaceuticals Announces Receipt Of Notification Of Deficiency From Nasdaq Regarding Requirement To Timely File Annual Report On Form 10-K

United States Court Of Appeals For The Federal Circuit Affirmed The Previously Announced Decision By The United States District Court For The District Of Delaware Finding That Drug Applications Referencing Eagle Pharmaceuticals&#39; Belrapzo (Bendamustine) Filed By Slayback Pharma And Apotex Did Not Infringe Eagle&#39;s Previously Issued &lsquo;483 Patent

Legal

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

-- BARHEMSYS&#xAE; (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV --
-- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 --
-- This post-hoc analysis of pivotal trials demonstrates that Barhemsys provides statistically significant (p=0.006) nausea relief in patients with established PONV --
-- A single 10 mg dose of intravenous amisulpride significantly reduced patients' nausea across multiple measures, including significant nausea, use of rescue medication, and evolution of nausea over time, and the adverse event profile was comparable between the placebo and 10 mg amisulpride arms –
-- Unique J-code for Barhemsys (J-0184) from CMS effective on January 1, 2024 --
&nbsp;
WOODCLIFF LAKE, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) ("Eagle" or the "Company") today announced that its abstract, a post-hoc analysis of two multicenter, placebo-controlled, Phase III studies evaluating amisulpride (a selective dopamine D2/D3 antagonist) as an antiemetic in patients with established postoperative nausea and vomiting, has been selected for a poster presentation at the 77th PGA (PostGraduate Assembly in Anesthesiology), being held December 8-11, 2023, in New York City. The conference is sponsored by the New York State Society of Anesthesiologists and is a global platform for presenting anesthesia's latest science and technologies.
"PONV contributes to prolonged post-anesthesia care unit and hospital stays and is distressing to patients and healthcare providers," stated Mike Greenberg, MD, Vice President of Medical Affairs at Eagle Pharmaceuticals. "In patients who experience PONV, nausea occurs much more frequently than vomiting. This analysis details pooled data on nausea-related outcomes from two Phase III trials. We are pleased to share that the proportion of patients with PONV experiencing substantial nausea in these studies was statistically significantly lower in the amisulpride 10 mg group than in the placebo group. We believe Barhemsys presents an opportunity for a much-needed therapeutic option for these patients," concluded Dr. Greenberg.
Details of the poster presentation are as follows:
Abstract Title: <a href="https://www.globenewswire.com/Tracker?data=YvAl2q1zR_4Bz4Kd4_m1PD_EGGf5yxkGhTTdev2tDLwV5QeEsXyk-ursGiuCsnuI7BOyOdkhgoCuZ07r0x5B3PR1PnL_GNamI3ltMce9DrnDCS8vKwd6Bqoj7GDlrRq2vUL4aaOFNR03jNlU3GXH-mfYiYKxq9Fx5IUKuFoJxgtkGo2rx2Y-WokvcBtNeRIo9tmhIqgfZ2R8kHak66sJ3hbHBhIo27G4rCKZ13Gfk288IlZuvHRo0rdE-E1EaHjnA66bcoDTC7l7pwbkQu51pnYNS3OBXTejklbe4xUeAK9DWlc_D23QljeYn2VN3klw">Amisulpride Provides Significant Nausea Reduction in Patients with Established Postoperative Nausea and Vomiting: Pooled Results from Two Phase III Trials</a>
 &nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Date:</td>
<td>December 10, 2023</td>
</tr>
<tr>
<td>Time:</td>
<td>3:30pm ET</td>
</tr>
<tr>
<td>Location:</td>
<td>Room 4, Monitor 7</td>
</tr>
</tbody>
</table>
</figure>

Events

Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City

<h3>Gainers</h3>
<ul>
<li>Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares increased by 45.2% to $4.59 during Thursday's after-market session. The company's market cap stands at $246.6 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 9.89% to $0.33. The market value of their outstanding shares is at $2.1 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares rose 9.63% to $0.12. The market value of their outstanding shares is at $3.9 million. </li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock moved upwards by 9.48% to $1.08. The company's market cap stands at $4.0 million. </li>
<li>Minerva Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTRS#NASDAQ">UTRS</a>) stock increased by 8.1% to $2.0. The market value of their outstanding shares is at $17.7 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) stock increased by 7.95% to $0.53. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ampio Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMPE#AMEX">AMPE</a>) shares declined by 20.5% to $4.58 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) stock declined by 9.23% to $6.0. The company's market cap stands at $26.5 million. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares decreased by 8.55% to $5.35. The company's market cap stands at $69.4 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 8.49% to $1.51. The market value of their outstanding shares is at $14.3 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) stock decreased by 8.34% to $4.63. The market value of their outstanding shares is at $4.5 million. </li>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) shares declined by 8.12% to $0.16. The company's market cap stands at $50.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AMPE

BIAF

CRBP

LMDX

NBSE

QNRX

UTRS

12 Health Care Stocks Moving In Thursday's After-Market Session

Shares of Patterson Companies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pdco#NASDAQ">PDCO</a>) moved lower during Wednesday&rsquo;s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Patterson posted adjusted earnings of 50 cents per share, missing market estimates of 58 cents per share. The company&rsquo;s quarterly sales came in at $1.65 billion versus expectations of $1.70 billion.
Patterson shares declined 14% to $27.01 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Vivos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvos#NASDAQ">VVOS</a>) shares jumped 135.2% to $10.53 after the company received first ever FDA 510(k) clearance for oral device treatment of severe obstructive sleep apnea.</li>
<li>China Pharma Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cphi#NYSE">CPHI</a>) climbed 86.7% to $0.1861. China Pharma reported completion of third party testing of dry eye disease therapeutic device.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) shares jumped 55.3% to $2.75. Envoy Medical, last week, reported a profit for the third quarter.</li>
<li>Avenue Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxi#NASDAQ">ATXI</a>) climbed 49.4% to $0.2841. Avenue Therapeutics recently posted a profit for the third quarter.</li>
<li>Biomea Fusion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmea#NASDAQ">BMEA</a>) shares jumped 40.1% to $13.93.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares gained 33.4% to $6.39 after gaining over 22% on Tuesday.</li>
<li>10X Capital Venture Acquisition Corp. II (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vcxa#NASDAQ">VCXA</a>) surged 30.3% to $10.61.</li>
<li>Rover Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rovr#NASDAQ">ROVR</a>) gained 28.4% to $10.93 after the company announced it agreed to be acquired by Blackstone in a $2.3 billion transaction.</li>
<li>Fluence Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flnc#NASDAQ">FLNC</a>) shares jumped 28% to $25.95 after reporting fourth-quarter results. Fluence Energy also initiated FY24 revenue guidance of $2.7 billion to $3.3 billion.</li>
<li>Ault Alliance, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ault#NYSE">AULT</a>) shares gained 25.6% to $0.1020. Ault Alliance announced its intention to commence an exchange offer to acquire shares of its common stock for up to $15 million in Series D preferred shares.</li>
<li>RedHill Biopharma Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdhl#NASDAQ">RDHL</a>) shares gained 24.3% to $2.8398 after jumping 128% on Tuesday. Redhill Biopharma recently announced the FDA has granted five years&#39; market exclusivity for Talicia.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cdt#NASDAQ">CDT</a>) climbed 21.5% to $3.5851.</li>
<li>Foot Locker, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fl#NYSE">FL</a>) surged 18% to $28.13 after the company reported better-than-expected third-quarter financial results.</li>
<li>QuantumScape Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qs#NYSE">QS</a>) climbed 17% to $6.70.</li>
<li>GameStop Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gme#NYSE">GME</a>) gained 16.3% to $15.70 after gaining around 13% on Tuesday.</li>
<li>NetApp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntap#NASDAQ">NTAP</a>) gained 14.4% to $89.42 after the company reported better-than-expected second-quarter financial results and issued FY24 EPS guidance above estimates.</li>
<li>Carvana Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvna#NYSE">CVNA</a>) rose 12% to $35.40. Carvana expanded same day delivery offering to Central Florida</li>
<li>residents.</li>
<li>vTv Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtvt#NASDAQ">VTVT</a>) surged 11.2% to $10.61. vTv Therapeutics recently announced a 1-for-40 reverse stock split.</li>
<li>Workday, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wday#NASDAQ">WDAY</a>) gained 8.5% to $257.42 after the company reported upbeat earnings results for its third quarter.</li>
<li>Hewlett Packard Enterprise Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hpe#NYSE">HPE</a>) climbed 8.5% to $16.84 following upbeat earnings.</li>
<li>Genesco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gco#NYSE">GCO</a>) climbed 7.9% to $34.88.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) gained 7.5% to $228.08 as the company posted better-than-expected earnings for its third quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) shares dipped 62.4% to $1.8766 after the company announced topline efficacy data from its Phase 3 trial of NE3107 for mild to moderate Alzheimer&#39;s disease.</li>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) fell 47.5% to $0.1081 after the company reported pricing of $4 million underwritten public offering.</li>
<li>Farfetch Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ftch#NYSE">FTCH</a>) fell 43.1% to $1.1943. Farfetch said it will not announce its third quarter financial results and will not hold its related conference call earlier scheduled for Nov. 29, 2023.</li>
<li>Seelos Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/seel#NASDAQ">SEEL</a>) fell 39.4% to $1.4380 after the company reported pricing of $5.55 million public offering.</li>
<li>BiomX Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/phge#NYSE">PHGE</a>) fell 32.1% to $0.38. BiomX announced safety and efficacy results from Part 2 of the Phase 1B/2A trial of BX004 for chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients, showing clinically meaningful improvement in pulmonary function.</li>
<li>Petco Health and Wellness Company, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/woof#NASDAQ">WOOF</a>) fell 23.6% to $2.93 after the company reported worse-than-expected third-quarter financial results and lowered FY23 adjusted EPS guidance below estimates.</li>
<li>Eagle Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egrx#NASDAQ">EGRX</a>) declined 22.2% to $6.40 after the company announced management change</li>
<li>Leslie&#39;s, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lesl#NASDAQ">LESL</a>) shares fell 21.5% to $4.56 after the company reported mixed fourth-quarter financial results.</li>
<li>Journey Medical Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/derm#NASDAQ">DERM</a>) declined 20% to $4.34.</li>
<li>CoreCard Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccrd#NYSE">CCRD</a>) declined 16.6% to $13.02 after the company reported a year-over-year decrease in third-quarter EPS results and worse-than-expected revenue results.</li>
<li>HNR Acquisition Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hnra#NASDAQ">HNRA</a>) fell 14.3% to $3.12. HNR Acquisition shares jumped 110% on Tuesday after the company gave a business update.</li>
<li>ESGL Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/esgl#NASDAQ">ESGL</a>) fell 13.1% to $1.13 after jumping 45% on Tuesday. ESGL recently announced a multi-year contract renewal with Singapore Refining Company Private Limited.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bdrx#NASDAQ">BDRX</a>) shares fell 12.6% to $3.6250. Biodexa Pharmaceuticals shares fell over 18% on Tuesday after the company announced an offering of 1,397,849 Class A units at an assumed public offering price of $2.79 per Class A unit.</li>
<li>Jabil Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jbl#NYSE">JBL</a>) fell 11.6% to $115.47 after the company updated first quarter, second quarter and FY24 revenue guidance below estimates.</li>
<li>Bilibili Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bili#NASDAQ">BILI</a>) dipped 8.2% to $12.25. Bilibili reported third-quarter FY23 revenue of $795.7 million (RMB5.8 billion), flat year-on-year, missing the consensus of $817.3 million.</li>
<li>Okta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/okta#NASDAQ">OKTA</a>) shares declined 4.4% to $69.40 following third-quarter results.</li>
<li>Verve Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/verv#NASDAQ">VERV</a>) shares fell 4% to $11.46 after the company reported pricing of public offering of common stock and concurrent private placement.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/36002198/salesforce-gears-up-for-q3-print-heres-a-look-at-recent-price-target-changes-by-the-most-accurate-a"> Salesforce Gears Up For Q3 Print; Here&#39;s A Look At Recent Price Target Changes By The Most Accurate Analysts</a>

Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Eagle Pharmaceuticals Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egrx#NASDAQ">EGRX</a>) Scott Tarriff, founder, president, and Chief Executive Officer, announced his resignation and retirement,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/11/g35998113/eagle-pharmaceuticals-announces-management-change" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">effective immediately</a>.
Michael Graves, Eagle Pharmaceuticals&#39; Chairman of the Board, has assumed the role of Interim Executive Chairman to lead the management team through this transition. The company will institute a CEO search for Tarriff&#39;s successor.
Michael Graves has served as Eagle&#39;s Board of Directors member since November 2013 and as Chairman of the Board since June 2016.&nbsp;
Concurrently, Eagle Pharmaceuticals received a notice that it is not currently in compliance with Nasdaq&#39;s continued listing requirements under the Listing Rule 5250(c)(1), as a result of the company&#39;s failure to file its 10-Q quarterly report for the quarter<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/11/g35998223/eagle-pharmaceuticals-announces-receipt-of-notification-of-deficiency-from-nasdaq-regarding-requir" style="background-image:initial; background-position:initial; background-size:initial; background-repeat:initial; background-attachment:initial; background-origin:initial; background-clip:initial; margin-top:0pt; margin-bottom:0pt; color:#4a6ee0" target="_blank">&nbsp;ended September 30, 2023</a>.
The Notice provides that the company has 60 calendar days from the date of the Notice, or until January 26, 2024, to submit a plan to regain compliance with the Rule to Nasdaq. If Nasdaq accepts the plan, Nasdaq may grant the company an exception of up to 180 calendar days until May 7, 2024, to regain compliance.
Price Action:&nbsp;EGRX shares are down 27.1% at $5.99 on the last check Wednesday.

WIIM

Eagle Pharmaceuticals shares are trading lower after the company announced it received notification of deficiency from the Nasdaq regarding the requirement to timely file quarterly report on Form 10-Q. Also, Founder, President and CEO Scott Tarriff announced his resignation effective immediately.

<h3>Gainers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) stock moved upwards by 312.8% to $18.12 during Wednesday's regular session. The company's market cap stands at $21.6 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock moved upwards by 86.37% to $0.19. The market value of their outstanding shares is at $5.9 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) shares moved upwards by 75.21% to $0.4. The company's market cap stands at $3.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares moved upwards by 52.34% to $2.7. The company's market cap stands at $52.7 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock moved upwards by 46.83% to $14.6. The market value of their outstanding shares is at $521.1 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock moved upwards by 37.19% to $12.91. The market value of their outstanding shares is at $26.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares decreased by 61.9% to $1.9 during Wednesday's regular session. The company's market cap stands at $71.7 million. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock declined by 50.02% to $0.28. The market value of their outstanding shares is at $12.8 million. </li>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) stock declined by 27.34% to $5.98. The market value of their outstanding shares is at $77.6 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) shares decreased by 18.71% to $4.39. The market value of their outstanding shares is at $81.2 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 15.76% to $3.5. The market value of their outstanding shares is at $2.4 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) shares fell 15.39% to $26.59. The company's market cap stands at $2.5 billion. As per the news, the Q2 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYTO

12 Health Care Stocks Moving In Wednesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Vivos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>) shares moved upwards by 132.6% to $10.21 during Wednesday's pre-market session. The company's market cap stands at $12.2 million. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) shares increased by 59.99% to $0.3. The company's market cap stands at $7.6 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock increased by 31.14% to $2.99. The company's market cap stands at $33.1 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) stock rose 24.74% to $12.4. The market value of their outstanding shares is at $442.7 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock moved upwards by 20.48% to $0.4. The company's market cap stands at $8.3 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock moved upwards by 17.62% to $0.4. The market value of their outstanding shares is at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) shares decreased by 14.3% to $7.05 during Wednesday's pre-market session. The market value of their outstanding shares is at $91.5 million. </li>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares fell 13.01% to $0.23. The company's market cap stands at $11.2 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares decreased by 10.3% to $10.7. The market value of their outstanding shares is at $682.2 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 9.78% to $10.8. The company's market cap stands at $63.5 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 9.49% to $0.39. The market value of their outstanding shares is at $14.8 million. </li>
<li>Patterson Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) stock decreased by 9.33% to $28.5. The company's market cap stands at $2.7 billion. As per the press release, Q2 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

CRIS

HSCS

KTTA

TRIB

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Eagle Pharmaceuticals Receives Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Eagle Pharmaceuticals Says Effective Immediately Scott Tarriff, Founder, President And CEO, Has Announced His Resignation And Retirement; Chairman Michael Graves To Serve As Interim Executive Chairman

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Eagle Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egrx#NASDAQ">EGRX</a>)</h3>
<ul>
<li>Eagle Pharmaceuticals announced it will be delaying the release of third-quarter results to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filling its Form 10-Q. The company&rsquo;s stock has a <a href="https://www.benzinga.com/quote/EGRX">52-week low of $8.32 </a>.</li>
<li>RSI Value: 21.46</li>
<li>EGRX Price Action: Shares of Eagle Pharmaceuticals fell 2.2% to close at $8.64 on Thursday.</li>
</ul>
<h3>Acutus Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/afib#NASDAQ">AFIB</a>)</h3>
<ul>
<li>Acutus Medical reported third-quarter financial results and announced strategic realignment of resources and corporate restructuring by approximately 65%. It <a href="https://www.benzinga.com/quote/AFIB"> has a 52-week low </a> of $0.16.</li>
<li>RSI Value: 24.39</li>
<li>AFIB Price Action: Shares of Acutus Medical fell 11% to close at $0.1851 on Thursday.</li>
</ul>
<h3>Becton, Dickinson and Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bdx#NYSE">BDX</a>)</h3>
<ul>
<li>Becton, Dickinson reported mixed fourth-quarter financial results and issued FY24 adjusted EPS and revenue guidance below estimates. &quot;We achieved another quarter, and another year, of strong performance through our talented team&#39;s execution of our BD2025 strategy and differentiated portfolio of medical technologies that are increasing healthcare efficiency and improving the lives of patients around the world,&quot; said Tom Polen, chairman, CEO and president of BD. The company&rsquo;s stock has a 52-week <a href="https://www.benzinga.com/quote/BDX"> low of $219.79.</a></li>
<li>RSI Value: 29.23</li>
<li>BDX Price Action: Shares of Becton, Dickinson gained 0.6% to close at $235.07 on Thursday.</li>
</ul>
<h3>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>)</h3>
<ul>
<li>Ventyx Biosciences posted in-line loss for the third quarter. Raju Mohan, Chief Executive Officer said, &ldquo;We look forward to providing important pipeline updates in the first quarter of 2024, including the VTX958 Phase 2 Crohn&rsquo;s disease interim efficacy analysis, an update from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis, Phase 2 data for our peripheral NLRP3 inhibitor, VTX2735, in CAPS, and Phase 1 data for our novel CNS penetrant NLRP3 inhibitor, VTX3232, in healthy volunteers.&rdquo; The company&rsquo;s 52-week low is $2.2750.</li>
<li>RSI Value: 10.50</li>
<li>VTYX Price Action: Shares of Ventyx Biosciences closed at $2.36 on Thursday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/11/35820854/jim-cramer-says-this-is-not-the-time-to-sell-this-online-gaming-platform-stock"> Jim Cramer Says &#39;This Is Not The Time To Sell&#39; This Online Gaming Platform Stock </a>

Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) is set to give its latest quarterly earnings report on Tuesday, 2023-11-14. Here's what investors need to know before the announcement.
Analysts estimate that Eagle Pharmaceuticals will report an earnings per share (EPS) of $1.06. 
Eagle Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 15.95% drop in the share price the next day.
Here's a look at Eagle Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.05</td>
<td>1.05</td>
<td>0.83</td>
<td>0.91</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.18</td>
<td>1.26</td>
<td>1.10</td>
<td>1.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-15.95%</td>
<td>-16.53%</td>
<td>0.43%</td>
<td>-9.94%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699898539_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Eagle Pharmaceuticals were trading at $9.27 as of November 10. Over the last 52-week period, shares are down 74.43%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/EGRX/earnings">To track all earnings releases for Eagle Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Eagle Pharmaceuticals's Earnings: A Preview

Eagle Pharmaceuticals shares are trading lower after the company announced it delayed its Q3 results to review potential adjustments relating to the reporting of sales of PEMFEXY prior to filling its Form 10-Q. Also, it expects to revise its FY23 guidance

Eagle Pharmaceuticals Delays Q3 2023 Results And Conference Call; Expects to File Its Form-10-Q By Nov. 14, 2023

Michael Graves, Board Member at Eagle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>), reported a large exercise of company stock options on October 31, according to a new SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000827871/000120919123053969//Archives/edgar/data/827871/000120919123053969/0001209191-23-053969-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday showed that Graves, Board Member at Eagle Pharmaceuticals, a company in the Health Care sector, just exercised stock options worth 9,360 shares of EGRX stock with an exercise price of $4.94.
Eagle Pharmaceuticals shares are trading down 0.0% at $13.73 at the time of this writing on Wednesday morning. Since the current price is $13.73, this makes Graves's 9,360 shares worth $128,512.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000827871">Check Out The Full List Of Eagle Pharmaceuticals's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Board Member at Eagle Pharmaceuticals Exercises Options Worth $128K

Eagle Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGRX#NASDAQ">EGRX</a>) ("Eagle" or the "Company") today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 ("the ‘813 patent") entitled "Pemetrexed Formulations." Eagle has submitted the patent for listing in the U.S. Food and Drug Administration's Orange Book.1 The ‘813 patent is directed to pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY&#xAE;. &nbsp;
The ‘813 patent will expire in 2036. This is the second patent to be listed in the Orange Book for PEMFEXY, and to date Eagle has not received any notice of a Paragraph IV certification for an application referencing PEMFEXY.
"The issuance of this patent is meaningful, as we continue to vigorously protect the commercial success of PEMFEXY and to add to the overall strength of our patent portfolio. PEMFEXY maintains a unique J-Code from CMS and sales remain strong, with a 24% share in the commercial (non-340B) pemetrexed market leaving the third quarter of 2023," stated Scott Tarriff, President and Chief Executive Office of Eagle.
About PEMFEXY PEMFEXY is a pemetrexed injection ready-to-dilute formulation for locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin; locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy, as maintenance treatment; locally advanced or metastatic nonsquamous non-small cell lung cancer after prior chemotherapy as a single agent; and malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin.

Eagle Pharmaceuticals Granted Patent For PEMFEXY

Eagle Pharmaceuticals Says Granted Unique J-Code And Pass-Through Status For BARHEMSYS From CMS

Eagle Pharmaceuticals Announced A Type C Meeting With The FDA Agreeing On A Path Forward To Advance The Development Of EA-114 For Breast Cancer In Post-menopausal Women. Eagle Currently Anticipates Filing A New Drug Application For EA-114 In 2024

Eagle Pharmaceuticals Inc (EGRX) has released an update to notify the public and investors about a regulation fd disclosure. Eagle Pharmaceuticals,...

Eagle Pharmaceuticals Updates Bendamustine IP Portfolio

Eagle Pharmaceuticals Inc (EGRX) stock is lower by -86.12% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives EGRX stock a score of  2 out of a possible 100. That rank is primarily influenced by a long-term technical score of 2. EGRX's rank also includes a short-term technical score of 3.  EGRX

Eagle Pharmaceuticals Inc (EGRX) Stock  Gains 9.62% This Week: Is It a Good Pick?

Eagle Pharmaceuticals Inc (EGRX) has released an update. Eagle Pharmaceuticals, Inc. is on the clock to file its overdue quarterly report after rec...

Eagle Pharmaceuticals Faces Nasdaq Delisting Deadline

Eagle Pharmaceuticals to cut 36% of workforce

Eagle Pharmaceuticals Inc (EGRX) stock has fallen -76.91% over the last 12 months. InvestorsObserver's proprietary ranking system, gives EGRX stock a score of  5 out of a possible 100. That rank is  influenced by a short-term technical score of 2. EGRX's rank also includes a long-term technical score of 13.  EGRX has an Ov

Is Eagle Pharmaceuticals Inc (EGRX) Stock a Smart Value?

Eagle Pharmaceuticals Inc (EGRX) has shared an update. Brian Cahill stepped down as CFO of Eagle Pharmaceuticals, and Steven Ratoff, a Board member...

Eagle Pharmaceuticals Announces CFO Transition and Leadership Changes

Eagle Pharmaceuticals announces resignation of Brian Cahill as CFO

Eagle Pharmaceuticals receives notification of deficiency from Nasdaq

Eagle Pharmaceuticals Inc (EGRX) has issued an announcement. Eagle Pharmaceuticals, Inc. is currently facing non-compliance issues with Nasdaq's li...

Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays

HROW, HCAT and EGRX are among after hour movers

ELYM

HCAT

HROW

IRON

MRVI

PYXS

TERN

Press Releases

EAGLE PHARMACEUTICALS 48 HOUR DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Eagle Pharmaceuticals, Inc.(EGRX) Investors of a Class Action Lawsuit and Upcoming Deadline

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. (EGRX)

EGRX Investors Have Opportunity to Lead Eagle Pharmaceuticals, Inc. Securities Fraud Lawsuit

EGRX DEADLINE TOMORROW: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Eagle Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important February 9 Deadline in Securities Class Action – EGRX

Eagle Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 9, 2024 to Discuss Your Rights - EGRX

EAGLE PHARMACEUTICALS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Eagle Pharmaceuticals To Contact Him Directly To Discuss Their Options

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Eagle Pharmaceuticals, Inc. - EGRX

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida